牛牛AI助理已提取核心訊息
On February 1, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, announced a significant milestone in the field of psychedelic-assisted therapies. The company's collaboration with Clarion Clinics has led to the Therapeutic Goods Administration (TGA) granting approval for Professor Suresh Sundram, co-founder and Head of Psychiatry at Clarion Clinics, to prescribe MDMA for Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at their Melbourne clinic. This approval follows the TGA's down-scheduling of these substances, allowing their use in clinical service delivery. Clarion Clinics, located in Abbottsford, Melbourne, is now the first dedicated psychedelic-assisted therapy clinic in Australia, designed to provide an optimal environment for treatment. Incannex Healthcare is pursuing U.S. FDA approval for its drug therapies and holds 19 granted patents and 30 pending applications. The company is listed on NASDAQ under the ticker IXHL.
On February 1, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, announced a significant milestone in the field of psychedelic-assisted therapies. The company's collaboration with Clarion Clinics has led to the Therapeutic Goods Administration (TGA) granting approval for Professor Suresh Sundram, co-founder and Head of Psychiatry at Clarion Clinics, to prescribe MDMA for Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at their Melbourne clinic. This approval follows the TGA's down-scheduling of these substances, allowing their use in clinical service delivery. Clarion Clinics, located in Abbottsford, Melbourne, is now the first dedicated psychedelic-assisted therapy clinic in Australia, designed to provide an optimal environment for treatment. Incannex Healthcare is pursuing U.S. FDA approval for its drug therapies and holds 19 granted patents and 30 pending applications. The company is listed on NASDAQ under the ticker IXHL.
2024年2月1日，臨床階段藥物開發公司Incannex Healthcare Inc. 宣佈了迷幻輔助療法領域的一個重要里程碑。該公司與Clarion Clinics的合作促使治療用品管理局（TGA）批准克拉麗奧診所聯合創始人兼精神病學負責人蘇雷什·桑德拉姆教授在其墨爾本診所開處方治療創傷後應激障礙（PTSD）的****和治療耐藥性抑鬱症（TRD）的迷幻藥處方。該批准是在TGA下調這些物質，允許它們用於臨床服務提供之後獲得的。位於墨爾本阿伯茨福德的Clarion Clinics現在是澳大利亞第一家專門的迷幻輔助治療診所，旨在提供最佳的治療環境。Incannex Healthcare正在尋求美國食品藥品管理局對其藥物療法的批准，並擁有19項已獲授權的專利和30項待處理的申請。該公司在納斯達克上市，股票代碼爲IXHL。
2024年2月1日，臨床階段藥物開發公司Incannex Healthcare Inc. 宣佈了迷幻輔助療法領域的一個重要里程碑。該公司與Clarion Clinics的合作促使治療用品管理局（TGA）批准克拉麗奧診所聯合創始人兼精神病學負責人蘇雷什·桑德拉姆教授在其墨爾本診所開處方治療創傷後應激障礙（PTSD）的****和治療耐藥性抑鬱症（TRD）的迷幻藥處方。該批准是在TGA下調這些物質，允許它們用於臨床服務提供之後獲得的。位於墨爾本阿伯茨福德的Clarion Clinics現在是澳大利亞第一家專門的迷幻輔助治療診所，旨在提供最佳的治療環境。Incannex Healthcare正在尋求美國食品藥品管理局對其藥物療法的批准，並擁有19項已獲授權的專利和30項待處理的申請。該公司在納斯達克上市，股票代碼爲IXHL。
有用
沒用